Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-21T22:10:49.419Z Has data issue: false hasContentIssue false
  • English
  • Français

Leptin and obesity

Published online by Cambridge University Press:  11 September 2013

Get access

In a nutshell

Leptin is a hormone released from fat that ‘signals’ the body's fat level, decreases appetite and food intake and increases energy expenditure. It also affects CVS and other systems.

Some therapeutic trials of leptin injections for obesity have been conducted with mixed results. Apart from rare cases of leptin deficiency, potential uses may include preventing weight rebound after weight reduction and treating lipodystrophy.

Type
Brief Report
Information
Arbor Clinical Nutrition Updates , Volume 240 , February 2006 , pp. 1 - 3
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Wynne, K. et al. Appetite control. J Endocrinol. 2005 Feb;184(2):291–318.CrossRefGoogle ScholarPubMed
2. Boss, O. et al. Adipose targets for obesity drug development. Expert Opin Ther Targets. 2006 Feb;10(1):119–34.Google Scholar
3. Speakman, JR. Obesity: the integrated roles of environment and genetics. J Nutr. 2004 Aug;134(8 Suppl):2090S–2105S.Google Scholar
4. Bowles, L. et al. Leptin: of mice and men? J Clin Pathol. 2001 Jan;54(1):1–3.Google Scholar
5. Bell-Anderson, KS. et al. Leptin as a potential treatment for obesity: progress to date. Treat Endocrinol. 2004;3(1):11–8.Google Scholar
6. Jiang, J. et al. Long-term control of food intake and body weight by hydrodynamics-based delivery of plasmid DNA encoding leptin or CNTF. J Gene Med. 2003 Nov;5(11):977–83.Google Scholar
7. Canavan, B. et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005 Oct;90(10):5779–85.Google Scholar
8. Chan, JL. et al. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab. 2005 Mar;90(3):1618–24.Google Scholar
9. Garofalo, C. et al. Leptin and cancer. J Cell Physiol. 2006 Apr;207(1):12–22.Google Scholar
10. Somasundar, P. et al. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg. 2003 Nov;186(5):575–8.Google Scholar
11. Helman, A. Grhelin and weight Arb Clin Nutr Upd 2002;138:1–2 Google Scholar
12. Zhang, JV. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005 Nov 11;310(5750):996–9.Google Scholar
13. Schwartz, MW. et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996 May;2(5):589–93.Google Scholar
14. Rodrigues, AM. et al. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J Clin Endocrinol Metab. 2002 Apr;87(4):1621–6.Google Scholar
15. Ceddia, RB. et al. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J. 2002 Aug;16(10):1163–76.CrossRefGoogle ScholarPubMed
16. Kobayashi, K. Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets. 2005 Jun;6(4):525–9.CrossRefGoogle ScholarPubMed
17. Heymsfield, SB. et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999 Oct 27;282(16):1568–75.Google Scholar
18. Hukshorn, CJ. et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab. 2000 Nov;85(11):4003–9.CrossRefGoogle ScholarPubMed
19. Westerterp-Plantenga, MS. et al. Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr. 2001 Oct;74(4):426–34.CrossRefGoogle ScholarPubMed
20. Mackintosh, RM. et al. The effects of leptin administration in non-obese human subjects. Obes Res. 2001 Aug;9(8):462–9.Google Scholar
21. Oral, EA. et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002 Feb 21;346(8):570–8.Google Scholar
22. Leibowitz, SF. et al. Leptin secretion after a high-fat meal in normal-weight rats: strong predictor of long-term body fat accrual on a high-fat diet. Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E258–67.Google Scholar
23. Mukherjee, R. et al. Leptin as a common link to obesity and hypertension. Timely Top Med Cardiovasc Dis. 2006 Jan 2;10:E1.Google Scholar
24. Mark, AL. et al. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002 Jul;20(7):1245–50.Google Scholar
25. Veniant, MM. et al. Leptin: from animals to humans. Curr Pharm Des. 2003;9(10):811–8.CrossRefGoogle ScholarPubMed
26. Montez, JM. et al. Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2537–42.Google Scholar
27. Proietto, J. et al. The therapeutic potential of leptin. Expert Opin Investig Drugs. 2003 Mar;12(3):373–8.Google Scholar